These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 35777046)

  • 1. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
    Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
    Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
    Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
    Front Oncol; 2021; 11():714267. PubMed ID: 34604051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
    Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
    Front Immunol; 2022; 13():976107. PubMed ID: 36091006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m
    Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
    Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m6A Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment.
    Zhang W; Xiao P; Tang J; Wang R; Wang X; Wang F; Ruan J; Yu S; Tang J; Huang R; Zhao X
    Front Immunol; 2022; 13():888650. PubMed ID: 35572541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
    Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
    Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
    Ye W; Huang T
    PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer.
    Sheng G; Wang T; Gao Y; Wu H; Wu J
    Sci Rep; 2023 Nov; 13(1):19670. PubMed ID: 37952076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Cell-Infiltration Characterization in Head and Neck Cancer.
    Yang Q; Xu F; Jian A; Yu H; Ye T; Hu W
    Front Cell Dev Biol; 2021; 9():803141. PubMed ID: 35198565
    [No Abstract]   [Full Text] [Related]  

  • 13. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
    Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
    Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 16. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
    Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
    Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
    BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
    Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
    BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
    Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.